Tempus AI (NASDAQ: TEM), a stock tied to former House Speaker Nancy Pelosi, is facing fresh skepticism on Wall Street despite its strong recent run.

Notably, on January 14, Pelosi disclosed her Congress trade of 50 call options with a $20 strike price expiring in January 2026. 

At one point, Tempus AI was her only profitable pick in 2025, as her portfolio took a steep hit during the broader market downturn following the tariff-induced selloff.

Since her trade, Tempus AI shares have surged about 131%, closing the last session at $73.78, up more than 3%. Year to date, the stock is up 115%.

Furthermore, the health technology company recently got a lift after reporting second-quarter 2025 results that topped expectations, with revenue of $314.6 million versus forecasts of $297.8 million. Loss per share came in narrower than projected at -$0.22, compared with the expected -$0.25.

Wall Street’s outlook on TEM share price 

Looking ahead, 11 analysts tracked by TipRanks expect a modest pullback over the next 12 months. The stock carries a consensus rating of ‘Moderate Buy’, with five ‘Buy’ and six ‘Hold’ ratings. No analysts currently recommend selling.

The average 12-month price target sits at $69.70, below the latest close, implying a 5.5% downside. Forecasts range from a low of $60.00 to a high of $75.00.

Following the earnings release, on August 13, TD Cowen’s Daniel Brennan raised his target from $62 to $72 while keeping a ‘Buy’ rating, citing stronger genomic volumes and growth potential in Ambry. The firm also lifted its outlook for the genomics segment but warned that management’s guidance points to slower growth in the second half of the year.

However, other analysts remain more cautious on TEM’s share price. Specifically, Stifel reiterated a ‘Hold’ with a $65 target, while banking giant Morgan Stanley maintained a ‘Buy’ but with a lower $68 target.

Featured image via Shutterstock